-Enhanced translation of IGF-1R, C-MYC, VEGF-A, and FGF1/2 [70,71].-Tumor development and apoptosis in CRC [72].-Cancer promotion or suppression in lung cancer and AML [70,73].-Ribosome heterogeneity: altered translation of mRNAs related to cell cycle, mitosis metabolism, oxidation–reduction, and intracellular transport [74].-Development stage of acute myeloid leukemia and its gene expression signature [73]. This evidence concerns the gene MYC and acute myeloid leukemia.